Loi Mervin V, Sultana Rehena, Nguyen Tuong Minh, Tia Shi Ting, Lee Jan Hau, O'Connor Daniel
Department of Paediatric Subspecialties, Children's Intensive Care Unit, KK Women's and Children's Hospital, Singapore, Singapore.
Center for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore.
Crit Care Explor. 2025 Jan 31;7(2):e1212. doi: 10.1097/CCE.0000000000001212. eCollection 2025 Feb 1.
Sepsis is a life-threatening medical emergency, with a profound healthcare burden globally. Its pathophysiology is complex, heterogeneous and temporally dynamic, making diagnosis challenging. Medical management is predicated on early diagnosis and timely intervention. Transcriptomics is one of the novel "-omics" technologies being evaluated for recognition of sepsis. Our objective was to evaluate the performance of host gene expression biosignatures for the diagnosis of all-cause sepsis in adults.
PubMed/Ovid Medline, Ovid Embase, and Cochrane databases from inception to June 2023.
We included studies evaluating the performance of host gene expression biosignatures in adults who were diagnosed with sepsis using existing clinical definitions. Controls where applicable were patients without clinical sepsis.
Data including population demographics, sample size, study design, tissue specimen, type of transcriptome, health status of comparator group, and performance of transcriptomic biomarkers were independently extracted by at least two reviewers.
Meta-analysis to describe the performance of host gene expression biosignatures for the diagnosis of sepsis in adult patients was performed using the random-effects model. Risk of bias was assessed according to the Quality Assessment of Diagnostic Accuracy Studies-2 tool. A total of 117 studies (n = 17,469), comprising 132 separate patient datasets, were included in our final analysis. Performance of transcriptomics for the diagnosis of sepsis against pooled controls showed area under the receiver operating characteristic curve (AUC, 0.86; 95% CI, 0.84-0.88). Studies using healthy controls showed AUC 0.87 (95% CI, 0.84-0.89), while studies using controls with systemic inflammatory response syndrome (SIRS) had AUC 0.84 (95% CI, 0.78-0.90). Transcripts with excellent discrimination against SIRS controls include UrSepsisModel, a 210 differentially expressed genes biosignature, microRNA-143, and Septicyte laboratory.
Transcriptomics is a promising approach for the accurate diagnosis of sepsis in adults and demonstrates good discriminatory ability against both healthy and SIRS control subjects.
脓毒症是一种危及生命的医疗急症,在全球范围内造成沉重的医疗负担。其病理生理学复杂、异质性强且随时间动态变化,这使得诊断具有挑战性。医疗管理基于早期诊断和及时干预。转录组学是正在评估用于识别脓毒症的新型“组学”技术之一。我们的目的是评估宿主基因表达生物标志物在诊断成人全因性脓毒症中的性能。
从创刊到2023年6月的PubMed/Ovid Medline、Ovid Embase和Cochrane数据库。
我们纳入了评估宿主基因表达生物标志物在使用现有临床定义诊断为脓毒症的成人中的性能的研究。适用时,对照组为无临床脓毒症的患者。
包括人群统计学、样本量、研究设计、组织标本、转录组类型、比较组健康状况以及转录组生物标志物性能等数据由至少两名审阅者独立提取。
使用随机效应模型进行荟萃分析,以描述宿主基因表达生物标志物在诊断成年患者脓毒症中的性能。根据诊断准确性研究质量评估-2工具评估偏倚风险。我们的最终分析纳入了117项研究(n = 17469),包括132个独立的患者数据集。转录组学诊断脓毒症相对于汇总对照组的性能显示,受试者工作特征曲线下面积(AUC,0.86;95%CI,0.84 - 0.88)。使用健康对照的研究显示AUC为0.87(95%CI,0.84 - 0.89),而使用全身炎症反应综合征(SIRS)对照的研究AUC为0.84(95%CI,0.78 - 0.90)。对SIRS对照具有出色区分能力的转录本包括UrSepsisModel(一个由210个差异表达基因组成的生物标志物)、microRNA - 143和Septicyte实验室。
转录组学是准确诊断成人脓毒症的一种有前景的方法,并且对健康和SIRS对照受试者均显示出良好的区分能力。